Jun 16, 2026GLP-1 vs. SGLT2: Which Cardiorenal Benefit Matters Most?GLP-1 receptor agonists and SGLT2 inhibitors can retain benefits together, but kidney, heart-failure, stroke, and MACE evidence differs.glp-1 receptor agonistssglt2 inhibitorscardiorenal outcomesRead article →
Jun 14, 2026Tirzepatide vs. Semaglutide: More Fat Loss, Not Proven Appetite EdgeA 28-week head-to-head trial found greater weight and fat loss with tirzepatide than semaglutide 1 mg—but appetite superiority remains unproven.tirzepatidesemaglutideweight lossRead article →